{
    "organizations": [],
    "uuid": "b2c40e3f4241dc9265b667ef25b60f2fda975f36",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-eiger-biopharma-says-phase-2-liber/brief-eiger-biopharma-says-phase-2-liberty-study-in-pulmonary-arterial-hypertension-did-not-meet-main-goal-idUSFWN1PB0TU",
    "ord_in_thread": 0,
    "title": "BRIEF-Eiger Biopharma Says Phase 2 Liberty Study In Pulmonary Arterial Hypertension Did Not Meet Main Goal",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 16 (Reuters) - Eiger Biopharmaceuticals Inc:\n* EIGER BIOPHARMACEUTICALS ANNOUNCES PHASE 2 LIBERTY STUDY IN PULMONARY ARTERIAL HYPERTENSION DID NOT MEET PRIMARY ENDPOINT\n* EIGER BIOPHARMACEUTICALS INC - EIGER BIOPHARMACEUTICALS ANNOUNCES PHASE 2 LIBERTY STUDY IN PULMONARY ARTERIAL HYPERTENSION DID NOT MEET PRIMARY ENDPOINT\n* EIGER BIOPHARMACEUTICALS INC - END OF PHASE 2 MEETING SCHEDULED FOR HDV IN FEBRUARY 2018\n* EIGER BIOPHARMACEUTICALS INC - NO SAFETY SIGNALS ATTRIBUTED TO UBENIMEX WERE IDENTIFIED IN PRELIMINARY ANALYSIS\n* EIGER BIOPHARMACEUTICALS - FURTHER ANALYSIS OF DATA, INCLUDING BIOMARKERS IS ONGOING, ALTHOUGH CO TO DISCONTINUE DEVELOPMENT OF UBENIMEX IN PAH\n* EIGER BIOPHARMACEUTICALS INC - WILL CONTINUE TO DEVELOP UBENIMEX FOR LYMPHEDEMA BASED ON ITS DISTINCT MECHANISM OF ACTION IMPACTING LYMPHANGIOGENESIS\n* EIGER BIOPHARMACEUTICALS INC - EIGER IS DEVELOPING UBENIMEX FOR LYMPHEDEMA IN ULTRA STUDY Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-16T21:12:00.000+02:00",
    "crawled": "2018-01-17T20:07:58.001+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "eiger",
        "biopharmaceuticals",
        "inc",
        "eiger",
        "biopharmaceuticals",
        "announces",
        "phase",
        "liberty",
        "study",
        "pulmonary",
        "arterial",
        "hypertension",
        "meet",
        "primary",
        "endpoint",
        "eiger",
        "biopharmaceuticals",
        "inc",
        "eiger",
        "biopharmaceuticals",
        "announces",
        "phase",
        "liberty",
        "study",
        "pulmonary",
        "arterial",
        "hypertension",
        "meet",
        "primary",
        "endpoint",
        "eiger",
        "biopharmaceuticals",
        "inc",
        "end",
        "phase",
        "meeting",
        "scheduled",
        "hdv",
        "february",
        "eiger",
        "biopharmaceuticals",
        "inc",
        "safety",
        "signal",
        "attributed",
        "ubenimex",
        "identified",
        "preliminary",
        "analysis",
        "eiger",
        "biopharmaceuticals",
        "analysis",
        "data",
        "including",
        "biomarkers",
        "ongoing",
        "although",
        "co",
        "discontinue",
        "development",
        "ubenimex",
        "pah",
        "eiger",
        "biopharmaceuticals",
        "inc",
        "continue",
        "develop",
        "ubenimex",
        "lymphedema",
        "based",
        "distinct",
        "mechanism",
        "action",
        "impacting",
        "lymphangiogenesis",
        "eiger",
        "biopharmaceuticals",
        "inc",
        "eiger",
        "developing",
        "ubenimex",
        "lymphedema",
        "ultra",
        "study",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}